Sebetralstat is the first and only oral, on-demand treatment approved for acute attacks of hereditary angioedema in patients aged 12 years and older . As a potent and selective plasma kallikrein inhibitor, Sebetralstat works by blocking the kallikrein-kinin system, reducing the conversion of high-molecular-weight kininogen to bradykinin, thereby decreasing vascular permeability and edema associated with HAE attacks . In the Phase III KONFIDENT trial, Sebetralstat demonstrated rapid symptom relief, with onset of relief occurring within 1.3 to 1.8 hours compared to 6.7 hours for placebo . The oral formulation of Sebetralstat allows for convenient self-administration, potentially improving patient compliance and quality of life compared to parenteral options . In analytical and quality control contexts, Sebetralstat serves as the primary reference standard for analytical method development, method validation, and quality control applications for branded formulations.
|
Parameter |
Specification |
|
Product Name |
Sebetralstat |
|
CAS Number |
1933514-13-6 |
|
Molecular Formula |
C26H26FN5O4 |
|
Molecular Weight |
491.51 g/mol |
|
Boiling Point |
762.3±60.0 °C(Predicted) |
|
Density |
1.29±0.1 g/cm3(Predicted) |
|
Appearance |
White solid |
|
Store Condition |
Store at -20 °C |
When your hereditary angioedema drug development program or analytical laboratory requires high-purity Sebetralstat, Cosperpharm delivers with the quality, documentation, and supply flexibility that pharmaceutical customers demand.
Supporting a new era in HAE treatment. Sebetralstat represents a paradigm shift in hereditary angioedema management as the first oral on-demand treatment . Our analytical release protocols include rigorous HPLC purity verification, identity confirmation, and residual solvent analysis — because the integrity of your reference standard matters for this groundbreaking therapy.
Documentation for regulatory submission. Every reference-grade shipment of Sebetralstat includes a Certificate of Analysis (COA) with batch-specific HPLC purity, chromatographic traceability, and analytical data — structured for direct insertion into your method validation package. Custom quality documentation is available upon request.
Flexible supply across all applications. Cosperpharm supplies Sebetralstat across the full spectrum of research applications — from milligram quantities for analytical method development and pharmacology studies, to larger quantities for research programs. R&D samples ship promptly; larger orders are supported with transparent lead times.
Technical support for the full research lifecycle. Our analytical chemistry team can advise on HPLC method development for sebetralstat-related substances, impurity identification and quantification, and stability-indicating method validation.
Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and analytical laboratories worldwide, with full customs documentation included. Volume discounts apply at larger scales, and we communicate lead times upfront — no hidden fees, no unexpected delays.
First-in-Class Oral Plasma Kallikrein Inhibitor
Sebetralstat is the first approved oral, on-demand treatment for hereditary angioedema, representing a significant advancement in HAE management . It is a potent and selective small-molecule plasma kallikrein inhibitor .
Rapid Onset of Action
In the Phase III KONFIDENT trial, Sebetralstat demonstrated rapid symptom relief, with onset of relief occurring within 1.3 to 1.8 hours compared to 6.7 hours for placebo . For laryngeal and abdominal attacks, median time to beginning of symptom relief was approximately 1.3 hours .
Convenient Oral Dosing
Sebetralstat is available as a 600 mg film-coated tablet for self-administration, with an optional second dose after 3 hours if warranted . This oral formulation offers patients a convenient alternative to injectable therapies .
Favorable Safety Profile
Sebetralstat is well tolerated, with gastrointestinal effects such as upper abdominal discomfort being the most commonly reported side effects. No severe or life-threatening incidents have been linked to the medication .
Proven Efficacy in Mucosal Attacks
Sebetralstat has demonstrated effectiveness in treating laryngeal and abdominal attacks of all severities, including potentially life-threatening mucosal attacks .
Q1: What is Sebetralstat used for?
A: Sebetralstat is an oral plasma kallikrein inhibitor approved for the on-demand treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older .
Q2: How does Sebetralstat work?
A: Sebetralstat inhibits plasma kallikrein, the enzyme responsible for converting high-molecular-weight kininogen to bradykinin, the key mediator of angioedema. This reduces vascular permeability and edema during HAE attacks .
Looking for Sebetralstat to support your HAE drug development, analytical method validation, or plasma kallikrein research? Cosperpharm delivers high-quality reference materials with the documentation you need. Get in touch — we're ready to assist.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
